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a b s t r a c t
Background: The risk of squamous cell carcinoma (SCC) is increased in solid organ transplant recipients
(OTRs), and preferential treatment modalities vary among clinicians.
Objectives: The purpose of this study was to survey dermatologists regarding practice patterns for elec-
trodesiccation and curettage (EDC) of SCC in OTRs and nontransplant patients.
Methods: An 18-question survey was sent to dermatologist members of the International Transplant Skin
Cancer Collaborative, Association of Professors of Dermatology, and American College of Mohs Surgery.
Differences in EDC practice patterns for treatment of SCC in OTRs and nontransplant patients were eval-
uated.
Results: Dermatologists in this study (N = 227) were more likely to treat SCC with EDC in nontransplant
patients (67.4%) than in OTRs (48.0%; P = .0003).
Dermatologists who perform EDC in both groups (n = 108) were unlikely to use EDC on the H-zone of
the face; they were more likely to EDC tumors on non-H-zone areas of the face and neck in nontransplant
patients compared to OTRs (P = .0007). Dermatologists were more likely to use EDC over surgery in non-
transplant patients compared to OTRs with the following demographics: dementia or psychiatric disease
(P = .04), multiple medical comorbidities (P = .03), or anticoagulation medications (P = .02).
Conclusions: In OTRs with SCC, 48% of clinicians would consider EDC. The main factors that affect the
decision to perform EDC include tumor location and patient comorbidities.
 2019 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The number of solid organ transplantations continues to rise,
with more than 33,000 transplantations performed in the United
States in 2016 (OPTN/SRTR 205 Annual Data Report, 2017).
Because of the necessary immunosuppressive regimens in solid
organ transplant recipients (OTRs), the incidence of cutaneous
malignancy is increased, with more than half of OTRs experiencing
at least one type of cutaneous malignancy (Euvrard et al., 2003).
Unlike the general population, where the incidence of basal cell
carcinoma is highest, the most common cutaneous malignancy
among OTRs is squamous cell carcinoma (SCC) (Garrett et al.,
2017). SCC in solid organ transplant patients presents at a younger
age and with more aggressive features, including a higher risk for
local recurrence, metastases, and mortality (Carucci et al., 2004;
Chockalingam et al., 2015). These features often make manage-
ment of SCC in this patient population more challenging.
SCC in transplant patients is commonly treated with surgical
excision or Mohs micrographic surgery (MMS). However, recent
evidence suggests that a number of clinicians also use destructive
methods such as electrodesiccation and curettage (EDC) for lower
risk lesions (Zwald and Brown, 2011). The purpose of this study
was to electronically survey dermatologists regarding their prac-
tice patterns for treatment of SCC in OTRs versus non–organ trans-
plant patients. Furthermore, we aimed to specifically delineate
differences in dermatologist practice patterns regarding use of
EDC for SCC in OTRs versus nontransplant patients. Our hypotheses
were that dermatologists are (1) less likely to use EDC for invasive
SCC in transplant patients compared with nontransplant patients
and (2) are less likely to use EDC in high-risk areas of the body
in transplant patients compared with nontransplant patients.
https://doi.org/10.1016/j.ijwd.2019.10.005
2352-6475/ 2019 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society.
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q Human subjects were included in this study. No animals were used in this
study. All portions of this study were conducted as a part of an Institutional Review
Board–approved study at Washington University School of Medicine; IRB
#201506014. All information presented in this study is HIPAA compliant.
⇑ Corresponding author.
E-mail address: hurste@wustl.edu (E.A. Hurst).
International Journal of Women’s Dermatology 6 (2020) 99–101
Contents lists available at ScienceDirect
International Journal of Women’s Dermatology
Methods
An 18-question voluntary survey was electronically adminis-
tered to members of the International Transplant Skin Cancer Col-
laborative (ITSCC), the Association of Professors of Dermatology
(APD), and the American College of Mohs Surgery (ACMS) (Supple-
mental Document). The survey was approved by the Washington
University School of Medicine Institutional Review Board. Provi-
ders were asked the same set of questions regarding treatment of
biopsy-proven SCC with EDC in OTRs versus nontransplant
patients. The study population included dermatologists with mem-
bership in any of the three organizations: ITSCC, APD, or ACMS. In
analysis of intrasubject variability for EDC practice patterns for
OTR and nontransplant patients, dermatologists who responded
‘‘never” to EDC on transplant patients were excluded. To detect a
20% difference between dermatologists who would consider EDC
in (1) transplant patients and (2) nontransplant patients, assuming
⍺ = 0.05 and power = 0.80, we would need 92 dermatologists per
group. A v2 analysis was used to compare the rate of EDC for solid
organ transplant patients between private and academic dermatol-
ogists. McNemar’s test was used to evaluate intrasubject variability
between EDC practice patterns for solid organ transplant and non-
transplant patients based on tumor and patient characteristics.
Results
A total of 227 surveys were returned, including 120 (52.9%)
from dermatologists in an academic setting and 107 (47.1%) from
private practice. The combined approximate active membership
of the ITSCC, the APD, and the ACMS is 2200 to 2300 members.
Therefore, the survey response rate approximates 10%, which is
an underestimate because a significant percentage of physicians
are members of more than one of the organizations. Of the 227 der-
matologists in this study, 118 (52.0%) would never use EDC for
invasive SCC in an OTR versus 74 (32.6%) who would never use
EDC for invasive SCC in a nontransplant patient (Table 1). Interest-
ingly, one physician would use EDC for invasive SCC in OTRs but
not in nontransplant patients. Overall, dermatologists were more
likely to treat a biopsy-proven SCC with EDC in nontransplant
patients than in OTRs (P = .0003). There was no difference in the
rate of EDC use for treatment of SCC in OTRs between private
and academic dermatologists (P = .67).
Among dermatologists who would consider performing EDC for
treatment of SCC in both OTRs and nontransplant patients
(n = 108), there was no difference in practice patterns for SCC
located on the H-zone of the face (defined as forehead, periorbital
area and temples, nose, cutaneous lip, and ears) (P = .22), extremi-
ties (P = .50), or trunk (P = .68) (Table 2). Dermatologists were more
likely to perform EDC for treatment of SCC on other areas of the
face and neck in nontransplant patients (29.6%) compared with
OTRs (15.7%; P = .0007). There was no difference in practice pat-
terns between the two groups of patients based on histology of
SCC, including well differentiated (P = 1.00), moderately differenti-
ated (P = .16), and poorly differentiated (P = 1.00) SCC.
In clinical practice, some clinicians may perform a biopsy on a
lesion and treat with EDC on the day of biopsy. In cases where
the final pathology report upstaged the lesion, clinicians were
asked if they would employ surgical excision or MMS based on
the final pathologic diagnosis. The decision to pursue further exci-
sion or MMS after EDC did not differ between OTRs and nontrans-
plant patients based on the following pathology findings: SCC
in situ (P = 1.00), well-differentiated (P = .68), well-differentiated
(P = .68), moderately differentiated (P = .77), and poorly differenti-
ated (P = .77) SCC.
Dermatologists were more likely to treat SCC with EDC over
surgical intervention in nontransplant patients compared with
OTRs with the following demographic characteristics: significant
dementia or psychiatric disease (P = .04), multiple medical comor-
bidities (P = .03), or blood thinners in addition to or stronger than
81 mg aspirin (P = .02). There was no difference in practice patterns
based on patients with a history of staphylococcal infection
(P = 1.00).
Discussion
More than 33,000 patients received a solid organ transplant in
2016, and the number of transplantations has steadily increased
over the last decade (OPTN/SRTR 2015 Annual Data Report,
2017). Potent immunosuppressive medications are required after
solid organ transplant to prevent transplant rejection. Likely
because of immunosuppression, there is a noted increase in cancer
Table 1
Clinician practice patterns for the management of SCC in OTRs and nontransplant







Frequency of EDC for SCC 0.0003
Never 118 (52.0%) 74 (32.6%)
Rarely (<10% of the time) 67 (29.5%) 84 (37.0%)
Sometimes 39 (17.2%) 63 (27.8%)
Frequently (>75% of the
time)
3 (1.3%) 6 (2.6%)
EDC, electrodesiccation and curettage; OTR, organ transplant recipient; SCC,
squamous cell carcinoma.
Table 2
Practice patterns for the management of SCC in OTRs and nontransplant patients in







Consider EDC of invasive SCC
based on tumor
characteristics
H-zone of face 4 (3.7%) 8 (7.4%) 0.22
Other face/neck 17 (15.7%) 32 (29.6%) 0.0007
Extremities 97 (89.8%) 103 (95.4%) 0.50
Trunk 103 (95.4%) 105 (97.2%) 0.68
Well-differentiated SCC 107 (99.1%) 106 (98.1%) 1.00
Moderately differentiated SCC 15 (13.9%) 20 (18.5%) 0.16
Poorly differentiated SCC 0 (0.0%) 1 (0.9%) 1.00
Further surgical excision after
EDC if upstaging on pathology
SCC in situ 2 (1.9%) 3 (2.8%) 1.00
Well-differentiated SCC 15 (13.9%) 13 (12.0%) 0.68
Moderately differentiated SCC 58 (53.7%) 58 (53.7%) 0.77
Poorly differentiated SCC 75 (69.4%) 82 (75.9%) 0.07
Perineural SCC or
depth > 4 mm
76 (70.4%) 83 (76.9%) 0.07
Consider EDC over surgical
intervention based on patient
demographic characteristics
Elderly (>85 years old) 86 (79.6%) 89 (82.4%) 0.75
Multiple medical
comorbidities
80 (74.1%) 89 (82.4%) 0.03
Dementia/psychiatric disease 82 (75.9%) 90 (83.3%) 0.04
Anticoagulation 22 (20.4%) 31 (28.7%) 0.02
History of staphylococcal
infections
9 (8.3%) 10 (9.3%) 1.00
Nursing home resident 36 (33.3%) 39 (36.1%) 0.25
No effect of above factors 16 (14.8%) 13 (12.0%) 0.50
EDC, electrodesiccation and curettage; OTR, organ transplant recipient; SCC, squa-
mous cell carcinoma.
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risk independent of infection (Engels et al., 2011). Among all malig-
nancies, the most common cancer after solid organ transplant is
SCC, with an incidence of 812 per 100,000 person-years (Garrett
et al., 2017). Risk factors for post-transplant skin cancer include
history of pretransplant skin cancer, male sex, white race, older
age at time of transplant, and a more recent transplant (Garrett
et al., 2017).
Important differences between SCC in transplant and nontrans-
plant patients have been noted. SCC tumors in OTRs are also more
likely to metastasize than SCC tumors in nontransplant patients
(Chockalingam et al., 2015). Interestingly, whereas the face and
neck are high-risk zones for SCC in the general population, there
is a noted increase in the risk of metastasis of the extremities
and trunk in immunosuppressed patients (Rowe et al., 1992). The
often aggressive phenotype of SCC in OTRs makes management dif-
ficult, and it is expected that clinicians will vary in practice pat-
terns for treatment of these lesions. No studies to date have
evaluated dermatologists’ use of EDC for treatment of SCC in OTRs.
Our first hypothesis was supported by our data, which stated
that clinicians were less likely to use EDC for invasive SCC in OTRs
compared to nontransplant patients. Among dermatologists who
would consider EDC in both patient populations, the only tumor
characteristic that differentially influenced management decisions
between the two groups was tumor location; clinicians were more
likely to treat SCC with EDC on non–H-zone areas of the face and
neck in nontransplant patients compared with OTRs. However,
the overall rate of EDC in this location was low in both groups,
weakening support for the second hypothesis, which stated that
clinicians were less likely to use EDC in high-risk areas of the body
in OTRs compared to nontransplant patients.
For both OTRs and nontransplant patients, there was a trend of
decreasing EDC use with increasing pathologic severity (from well-
differentiated to moderately to poorly differentiated SCC). No one
surveyed would use EDC for poorly differentiated SCC in an OTR,
and only one respondent would use EDC for poorly differentiated
SCC in a nontransplant patient. Because of this trend, we were
likely underpowered to detect any differences in management
between OTRs and non-OTRs based on pathologic severity. Patient
demographic characteristics that differentially affected manage-
ment of SCC in OTRs versus nontransplant patients included mul-
tiple medical comorbidities, significant dementia or psychiatric
disease, and anticoagulation.
EDC is a reasonable approach for many localized skin tumors,
with well-documented efficacy in the literature (Goldman, 2002;
Reschly and Shenefelt, 2010). However, there are no randomized
controlled studies that evaluate EDC for treatment of SCC in OTRs.
Based on available data, Stasko et al. (2004) have introduced a sim-
ple algorithm for managing SCC in OTRs. Aggressive EDC is an
option for superficial, slowly growing SCC, whereas surgical exci-
sion or MMS is preferred for larger tumors and SCC of the face or
neck. The results herein are consistent with these recommenda-
tions. Not surprisingly, clinicians in our study were unlikely to per-
form EDC in the H-zone area of the face (forehead, periorbital area
and temples, nose, cutaneous lip, and ears) regardless of transplant
status, because EDC is not considered the standard of care in these
areas. Although EDC is used in both transplant and nontransplant
populations for SCC, some aggressive SCCs require more definitive
surgical treatment with margin assessment to reduce the chance of
residual tumor and subsequent metastasis and mortality.
The primary limitations of this study are inherent to studies
using surveys, including selection and recall bias. In addition, we
are unable to calculate the exact response rate to our survey
because many physicians are members of more than one of the
surveyed organizations, but we are able to estimate a 10% response
rate. This is obviously a small proportion of all practicing dermatol-
ogists. Among our respondents, the proportion of dermatologists in
academic practice was larger than the general dermatology work-
force, and overrepresentation of academia may have influenced
our results. However, there was no difference in the rate of EDC
for treatment of SCC in OTRs in academia compared with private
practice, making a large effect from academic overrepresentation
unlikely. Additionally, we did not categorize surveyed dermatolo-
gists by their primary practice pattern (e.g., general dermatology,
medical dermatology, surgical/procedural dermatology), as use of
EDC may differ based on subspecialty type. Finally, although it is
clear from our results that a sizable portion of clinicians would
consider EDC for treatment of SCC in OTRs, there are no studies
that directly compare outcomes of EDC to excision or MMS in this
population. Further prospective studies would be helpful to stratify
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